[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.142.229. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1993

Long-term Suppression of Recurrent Genital Herpes With AcyclovirA 5-Year Benchmark

Author Affiliations

From the Departments of Dermatology (Dr Goldberg) and Obstetrics and Gynecology (Dr Kaufman), Baylor College of Medicine, Houston, Tex; University of Osteopathic Medicine and Health Sciences, Des Moines, Iowa (Dr Kurtz); University of California at San Francisco (Dr Conant); Fairfax Hospital, Falls Church, Va (Dr Eron); and Burroughs Wellcome Co, Research Triangle Park, NC (Dr Batenhorst and Ms Boone).

Arch Dermatol. 1993;129(5):582-587. doi:10.1001/archderm.1993.01680260052005
Abstract

• Background and Design.—  This multicenter trial (19 sites) was initiated in 1984 in more than 1100 immunocompetent individuals with a history of frequently recurring genital herpes (mean, ≥12 episodes per year). The first year of this suppressive therapy trial was placebo controlled, with acyclovir being provided for episodic treatment in both groups. Thereafter, patients were treated with open-label acyclovir suppressive therapy on a long-term basis (400 mg twice daily) to continue to assess its long-term safety and efficacy. Complete data are available on 389 of the 430 patients who began the fifth year of the study.

Results.—  Patients were seen quarterly for review of diaries and clinical laboratory evaluations. The percentage of patients recurrence free for any 3-month quarter of the fifth year ranged from 86% to 90%. The mean annual number of recurrences per patient declined from 1.7 during the first year to 0.8 during the fifth year of suppressive therapy. The frequency of false prodromes has also decreased over time. More than 20% of the patients receiving suppressive therapy for 5 years have been recurrence free the entire time. The duration of herpetic outbreaks during suppressive therapy has not changed.

Conclusion.—  This study extends the safety and efficacy profile of oral acyclovir in the suppression of genital herpes to 5 years. The majority of the patients were recurrence free on an annual basis during suppressive therapy. Therapy was well tolerated. Acyclovir usage was not associated with serious side effects or cumulative toxicity.(Arch Dermatol. 1993;129:582-587)

×